The combination of cyclophosphamide, vincristine, and prednisone (CVP) is one of several standard treatment options for advanced follicular lymphoma. This, like similar chemotherapeutic regimens, induces response rates of 60% to 80%, with a median response duration of under 2 years. Rituximab, a chimeric monoclonal antibody against CD20, is active in follicular lymphoma, both as monotherapy and in combination with chemotherapy. Previously untreated patients with stages III to IV follicular lymphoma were randomly assigned to receive either 8 cycles of CVP plus rituximab (R-CVP; n = 162) or CVP (n = 159). Overall and complete response rates were 81% and 41% in the R-CVP arm versus 57% and 10% in the CVP arm, respectively (P < .0001). At a med...
International audienceAnti-CD20-containing chemotherapy regimens have become the standard of care fo...
The incidence of follicular lymphoma, a low-grade malignant B-cell lymphoma, is increasing in most A...
Anti-CD20-containing chemotherapy regimens have become the standard of care for patients with follic...
Purpose Although rituximab (R) is commonly used for patients with advanced follicular lymphoma (FL) ...
Therapeutic options for relapsed or refractory follicular lymphoma include combination chemotherapy,...
Purpose. Although rituximab (R) is commonly used for patients with advanced follicular lymphoma (FL...
PURPOSE: Although rituximab (R) is commonly used for patients with advanced follicular lymphoma (FL...
Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine, and prednison...
Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine, and prednison...
Rituximab, a chimeric monoclonal antibody directed against the CD20 antigen, has been shown to be ac...
Rituximab, a chimeric monoclonal antibody directed against the CD20 antigen, has been shown to be ac...
International audienceAnti-CD20-containing chemotherapy regimens have become the standard of care fo...
The incidence of follicular lymphoma, a low-grade malignant B-cell lymphoma, is increasing in most A...
Anti-CD20-containing chemotherapy regimens have become the standard of care for patients with follic...
Purpose Although rituximab (R) is commonly used for patients with advanced follicular lymphoma (FL) ...
Therapeutic options for relapsed or refractory follicular lymphoma include combination chemotherapy,...
Purpose. Although rituximab (R) is commonly used for patients with advanced follicular lymphoma (FL...
PURPOSE: Although rituximab (R) is commonly used for patients with advanced follicular lymphoma (FL...
Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine, and prednison...
Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine, and prednison...
Rituximab, a chimeric monoclonal antibody directed against the CD20 antigen, has been shown to be ac...
Rituximab, a chimeric monoclonal antibody directed against the CD20 antigen, has been shown to be ac...
International audienceAnti-CD20-containing chemotherapy regimens have become the standard of care fo...
The incidence of follicular lymphoma, a low-grade malignant B-cell lymphoma, is increasing in most A...
Anti-CD20-containing chemotherapy regimens have become the standard of care for patients with follic...